Again I implore you to an in person debate. It would be more productive in the overall understanding of the different oncology approaches. I want to discuss with you the downside of monoclonal antibodies in solid tumors vs the efficacy in blood cancers where tumor hetrogenity comes into play. It is my belief you fail to understand the pros and cons. I feel that a tete a tete would be much more productive. We can even agree to embargo the discussion. What say you?
My opinion is that pv-10 will work just fine as a mono therapy for stage three and below. Tumor burden and mets remain to be a problem for stage four. This requires a more systemic approach. That being said it will require the stimulus of the immune system. I call it the Mazda Method (vroom vroom) which entails stepping on the gas ( front end primer approach ...a pv-10 primer...stepping on the gas) combined with a back end approach ( checkpoint inhibitor....releasing the brakes). I predicted this to you about two years ago....because I understood the cascade from autophagy to immune response. The lack of understanding that cascade....recently eludicated partially by moffitt...partially...has held back progress with checkpoint inhibitor efficacy. I have found I am ahead of the industry in understanding the MOA of immune stimulus. But they are catching up.
Personally I would short them in the long term. I do not believe in their tech as of the moment. Monoclonal antibodies tech such as Kite and Juno have a sound basis in blood cancers because of the lack of cancer heterogeneity. But the blocking of GS-CFM does not have me convinced of that route. I back NTTG if he is short.
I think so. The first data that will show player ability will be combo data with keytruda. The phase one trial is 24 patients and that trial is already underway. I expect results by March if not sooner. Please refer to my posts on investor village on my opines on the matter.
Fair enough reply...but what phase are they reporting first patient? In phase one and two you can see that data. In phase three the data should not be seen...unless they feel the need to violate the closed trial and report on the cro. In honesty I have not checked their trials for the moment...would you care to clarify?
It is my opinion that those streamlining procedures needed to be eludicated in order to determine the protocols. Per the Cfda website all the cfda new procedures go in to effect dec. 1st. I posted the links on investor village but feel free to verify my findings.
I am aware of one drug that was around 250th in line in the ind process in China. Then the new CFDA decree that all pharmas do a self audit of their data for Ind application be done. That pharma moved to number one position. There is no company info where the ind is....it doesn't matter anyway...Eric said he had another route to China. I assume that is Hong Kong and Singapore. If so that will speed things up..but that remains to be seen and is just an opinion for the present.
There is no evidence of where the ind is yet. Keep it real Larry. I appreciate your effort but keep things factual.
I'm not at your beckon call...I have been busy. Please read then bash my latest posts on investor village. Thanks for all your efforts at pointing me out...your making me famous. Where that newt...where's my in person debate? Why won't the rest of you encourage the tete a tete? Is it because your false figure of authority will be dethroned? I await your biased retorts.
You like that term....I am glad. Some sites are up...others I assume will be up soon....more after that then?
Now if you are going to whip out the Ist patient treated card....I am assuming that an open site will be treating patients already. Now why doesn't Eric talk about that? I don't work for the company....I have no idea. But he said early on before any site went up that he would not be reporting the patient by patient status of the trial. I really can't blame him.....both trolls and fans would be asking every few weeks how "many more now?"
Not coordinated....we post our ideas daily.....you can look at the record. The same can be said of you bashing the company to drive the share price down.....btw....why are you concerned about a stock you do not own? Who pays you to bash? Why do you continue your troll behavior? You are great amusement for me......threatening me.....knock yourself out....I do not advise people to buy or sell...always check with your financial advisors. What little gremlin are you to post all day long things against the company.....can you give a reason? You must be retired to have all the time necessary to sling the insults.
Did "Take It in the Can" make a bad trade?....thus taking it in the can? Driving the retired, time wasting troll to post vomitous drivel all day long?
In case he deletes his post again:
take_it_in_the_can • 12 minutes ago
It should be clear to existing/prospective Provectus shareholders that it is not clear to company management how much more data, broadly speaking, is required for some sort of combination therapy deal with a Big Pharma having an immune checkpoint inhibitor (and/or a targeted therapy) under [mostly-to-exclusively] terms acceptable to Provectus to materialize.
WOW! Well shareholders, I think it should now be clear to you that this is a deliberate pump by Dom to get you to invest/buy more shares. FUNNY how this hits the site the day the stock falls below .50. Coincidence? Hardly. This guy is just like Vorlon and Alan ......a paid pumper. Vorlon is telling everyone at iv that the Chinese fda snafu is cleared up and liver protocols are good to go and that the combo trial is recruiting and now we get this. WOW. If this isn't a coordinated pump I don't know what is, I can't wait to read the bullspit Alan will be coming out with.
BEWARE HOLDERS: THE D TEAM is at work again....i.e.. the Deception Team! Less